[go: up one dir, main page]

BR112015032388A2 - métodos e composições para as vacinas contra o vírus da dengue - Google Patents

métodos e composições para as vacinas contra o vírus da dengue

Info

Publication number
BR112015032388A2
BR112015032388A2 BR112015032388A BR112015032388A BR112015032388A2 BR 112015032388 A2 BR112015032388 A2 BR 112015032388A2 BR 112015032388 A BR112015032388 A BR 112015032388A BR 112015032388 A BR112015032388 A BR 112015032388A BR 112015032388 A2 BR112015032388 A2 BR 112015032388A2
Authority
BR
Brazil
Prior art keywords
dengue virus
methods
compositions
virus vaccines
glycoprotein
Prior art date
Application number
BR112015032388A
Other languages
English (en)
Other versions
BR112015032388A8 (pt
Inventor
DESILVA Aravinda
Yount Boyd
Baric Ralph
Messer William
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of BR112015032388A2 publication Critical patent/BR112015032388A2/pt
Publication of BR112015032388A8 publication Critical patent/BR112015032388A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

a presente invenção refere-se a fornecer as composições e aos métodos de uso compreendendo uma glicoproteína e do vírus quimérico da dengue compreendendo uma estrutura da glicoproteína e do vírus da dengue, que compreende as substituições de aminoácidos que introduzem um epítopo que é reconhecido por um anticorpo de um sorotipo do vírus da dengue que é diferente do sorotipo do vírus da dengue da estrutura da glicoproteína e do vírus da dengue.
BR112015032388A 2013-06-26 2014-06-26 glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições BR112015032388A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839687P 2013-06-26 2013-06-26
PCT/US2014/044410 WO2014210358A1 (en) 2013-06-26 2014-06-26 Methods and compositions for dengue virus vaccines

Publications (2)

Publication Number Publication Date
BR112015032388A2 true BR112015032388A2 (pt) 2017-07-25
BR112015032388A8 BR112015032388A8 (pt) 2020-01-14

Family

ID=52142690

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015032388A BR112015032388A8 (pt) 2013-06-26 2014-06-26 glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições

Country Status (12)

Country Link
US (2) US10053493B2 (pt)
EP (2) EP3590955A1 (pt)
JP (2) JP6525984B2 (pt)
KR (1) KR20160027019A (pt)
CN (2) CN110734500A (pt)
AU (2) AU2014302282B2 (pt)
BR (1) BR112015032388A8 (pt)
CA (1) CA2918644A1 (pt)
ES (1) ES2745431T3 (pt)
MX (2) MX365957B (pt)
SG (1) SG11201510617WA (pt)
WO (1) WO2014210358A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212672A4 (en) * 2014-11-02 2018-04-25 The University of North Carolina at Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
TWI769185B (zh) 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
WO2018217906A1 (en) * 2017-05-23 2018-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus serotype 4 epitopes
US11484586B2 (en) 2017-06-14 2022-11-01 Thomas Jefferson University Compositions and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies
WO2023056335A1 (en) * 2021-09-30 2023-04-06 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
CN116716322B (zh) * 2023-05-12 2024-05-31 中山大学 一种denv-3全长感染性克隆及其构建方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
PL170980B1 (pl) 1992-06-25 1997-02-28 Smithkline Beecham Biolog Szczepionka PL PL PL PL PL PL PL
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
WO2006085983A2 (en) 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
WO2006025990A2 (en) * 2004-07-27 2006-03-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Diseases Control And Prevention Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
US8029802B2 (en) * 2004-10-20 2011-10-04 Sanofi Pasteur Biologics Co. Vaccines against Japanese encephalitis virus and West Nile virus
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2550292B1 (en) * 2010-03-24 2017-11-22 Research Development Foundation Flavivirus host range mutations and uses thereof
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
WO2012027473A2 (en) 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
EA201390874A1 (ru) * 2010-12-14 2013-12-30 Нэшнл Юниверсити Оф Сингапур Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
AU2012326079B2 (en) 2011-10-20 2017-01-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dengue virus E-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
WO2013151764A1 (en) 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes

Also Published As

Publication number Publication date
JP2019195328A (ja) 2019-11-14
MX2016000235A (es) 2016-08-11
CN105473603B (zh) 2019-10-25
MX365957B (es) 2019-06-20
EP3013852A1 (en) 2016-05-04
JP2016523912A (ja) 2016-08-12
AU2014302282A1 (en) 2016-02-11
CN105473603A (zh) 2016-04-06
BR112015032388A8 (pt) 2020-01-14
SG11201510617WA (en) 2016-01-28
CA2918644A1 (en) 2014-12-31
WO2014210358A1 (en) 2014-12-31
KR20160027019A (ko) 2016-03-09
CN110734500A (zh) 2020-01-31
EP3590955A1 (en) 2020-01-08
AU2018278927A1 (en) 2019-01-17
US10053493B2 (en) 2018-08-21
AU2014302282B2 (en) 2018-09-13
US20190225654A1 (en) 2019-07-25
EP3013852A4 (en) 2017-02-15
US20160257719A1 (en) 2016-09-08
JP6525984B2 (ja) 2019-06-05
ES2745431T3 (es) 2020-03-02
MX2019007252A (es) 2019-08-16
US10870682B2 (en) 2020-12-22
EP3013852B1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
CY1121560T1 (el) Ανοσογονικη συνθεση
BR112018007017A2 (pt) polipeptídeos
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201690667A1 (ru) Композиции, содержащие антитело к pdl1
CL2015002865A1 (es) Composiciones de limpieza que contienen una poliéteramina
BR112014024612A2 (pt) ácido nucleico, polipeptídeo, glicoproteína e quimérica, epítopo de vírus da dengue, partícula semelhante a flavivírus quimérico (vlp), flavivírus quimérico, e métodos in vitro para identificar um anticorpo neutralizante e para identificar uma composição imunogênica contra um vírus da dengue
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
MX2018003827A (es) Anticuerpos anti-cd19 humano con alta afinidad.
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
BR112016029040A2 (pt) método de uso de um composto quaternário de amônia, um polissacarídeo catiônico e um polissacarídeo não iônico
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
BR112017009623A2 (pt) composição de limpeza
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
MX2021010060A (es) Produccion de virus en huevos aviares.
MX2016003660A (es) Conjugados de partícula similar a virus para el diagnóstico y tratamiento de tumores.
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
BR112017008952A2 (pt) métodos e composições para vírus recombinantes da dengue para desenvolvimento de vacina e diagnóstico
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
MX2016010263A (es) Composiciones estabilizadas de silicato y su uso como composiciones antitranspirantes.
MX378108B (es) Anticuerpos anti-met y composiciones.
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
BR112017004197A2 (pt) composições de vacina contra doenças do vírus da dengue

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2676 DE 19-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.